{"id":691441,"date":"2022-10-03T16:10:41","date_gmt":"2022-10-03T20:10:41","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-20\/"},"modified":"2022-10-03T16:10:41","modified_gmt":"2022-10-03T20:10:41","slug":"karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-20","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-20\/","title":{"rendered":"Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"legendSpanClass\"><br \/>\n          <span class=\"xn-location\">NEWTON, Mass.<\/span><br \/>\n        <\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Oct. 3, 2022<\/span><\/span> \/PRNewswire\/ &#8212; Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that on <span class=\"xn-chron\">September 30, 2022<\/span> (the Grant Date), the Company granted\u00a0a stock option to purchase 1,200 shares of Karyopharm&#8217;s common stock and an award of 800 restricted stock units (RSUs) to one newly-hired employee. The stock option has an exercise price of\u00a0$5.46 per share, the closing price of Karyopharm&#8217;s common stock on\u00a0the Grant Date. The stock option will vest over four years, with 25% of the total number of shares underlying the stock option vesting on the one-year anniversary of the employee&#8217;s employment commencement date and 1\/48th of the total number of shares vesting monthly thereafter. The RSU award will vest over four years, with 25% percent of the shares underlying the RSU award vesting on each of the four consecutive anniversaries of the employee&#8217;s employment commencement date.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/1890042\/Karyopharm_Therapeutics_Logo.html\" target=\"_blank\" rel=\"nofollow noopener\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/1890042\/Karyopharm_Therapeutics_Logo.jpg\" title=\"(PRNewsfoto\/Karyopharm Therapeutics Inc.)\" alt=\"(PRNewsfoto\/Karyopharm Therapeutics Inc.)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>In addition, the Company granted a stock option to purchase 100,000 shares of Karyopharm&#8217;s common stock and an award of 65,000 RSUs to <span class=\"xn-person\">Lisa DiPaolo<\/span>, the Company&#8217;s newly hired Executive Vice President, Chief Human Resources Officer &amp; Head of People and Culture, on the Grant Date. The option has an exercise price of <span class=\"xn-money\">$5.46<\/span> per share, the closing price of Karyopharm&#8217;s common stock on the Grant Date. The stock option will vest over four years, with 25% of the total number of shares underlying the stock option vesting on the one-year anniversary of Ms. DiPaolo&#8217;s employment commencement date and 1\/48th of the total number of shares vesting monthly thereafter.The RSU award will vest as to 50% of the shares underlying the award, on each of the two consecutive anniversaries of Ms. DiPaolo&#8217;s employment commencement date.<\/p>\n<p>Each of these equity awards were granted pursuant to the Company&#8217;s 2022 Inducement Stock Incentive Plan, as amended, as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4). The vesting of each inducement award is subject to the employee&#8217;s continued service as an employee of, or other service provider to, Karyopharm through the applicable vesting dates. In addition, each stock option and RSU award will be immediately exercisable in full if, on or prior to the first anniversary of the consummation of a &#8220;change in control event,&#8221; the employee&#8217;s employment is terminated for &#8220;good reason&#8221; by the employee or terminated without &#8220;cause&#8221; by Karyopharm (as such terms are defined in the applicable stock option or RSU agreement).<\/p>\n<p>\n        <b>About Karyopharm Therapeutics<\/b>\n      <\/p>\n<p>Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company pioneering novel cancer therapies. Since its founding, Karyopharm has been the industry leader in oral Selective Inhibitor of Nuclear Export (SINE) compound technology, which was developed to address a fundamental mechanism of oncogenesis: nuclear export dysregulation. Karyopharm&#8217;s lead SINE compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO\u00ae (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications and has received regulatory approvals in various indications in a growing number of ex-U.S. territories and countries, including <span class=\"xn-location\">Europe<\/span> and the <span class=\"xn-location\">United Kingdom<\/span> (as NEXPOVIO\u00ae) and <span class=\"xn-location\">China<\/span>, <span class=\"xn-location\">Singapore<\/span>, <span class=\"xn-location\">Canada<\/span>, <span class=\"xn-location\">Israel<\/span>, <span class=\"xn-location\">South Korea<\/span> and <span class=\"xn-location\">Australia<\/span>. Karyopharm has a focused pipeline targeting multiple high unmet need cancer indications, including in multiple myeloma, endometrial cancer, myelodysplastic syndromes and myelofibrosis. For more information about our people, science and pipeline, please visit <a href=\"http:\/\/www.karyopharm.com\" rel=\"nofollow\">www.karyopharm.com<\/a>, and follow us on Twitter at @Karyopharm and LinkedIn.<\/p>\n<p>XPOVIO<sup>\u00ae<\/sup> and NEXPOVIO<sup>\u00ae<\/sup> are registered trademarks of Karyopharm Therapeutics Inc.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder2\"><\/div>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=NE91188&amp;sd=2022-10-03\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow noopener\" href=\"https:\/\/www.prnewswire.com\/news-releases\/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-301639356.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-301639356.html<\/a><\/p>\n<p>SOURCE  Karyopharm Therapeutics Inc.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=NE91188&amp;Transmission_Id=202210031605PR_NEWS_USPR_____NE91188&amp;DateId=20221003\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire NEWTON, Mass. , Oct. 3, 2022 \/PRNewswire\/ &#8212; Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that on September 30, 2022 (the Grant Date), the Company granted\u00a0a stock option to purchase 1,200 shares of Karyopharm&#8217;s common stock and an award of 800 restricted stock units (RSUs) to one newly-hired employee. The stock option has an exercise price of\u00a0$5.46 per share, the closing price of Karyopharm&#8217;s common stock on\u00a0the Grant Date. The stock option will vest over four years, with 25% of the total number of shares underlying the stock option vesting on the one-year anniversary of the employee&#8217;s employment commencement date and 1\/48th of the total number of shares vesting monthly &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-20\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-691441","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-20\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire NEWTON, Mass. , Oct. 3, 2022 \/PRNewswire\/ &#8212; Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that on September 30, 2022 (the Grant Date), the Company granted\u00a0a stock option to purchase 1,200 shares of Karyopharm&#8217;s common stock and an award of 800 restricted stock units (RSUs) to one newly-hired employee. The stock option has an exercise price of\u00a0$5.46 per share, the closing price of Karyopharm&#8217;s common stock on\u00a0the Grant Date. The stock option will vest over four years, with 25% of the total number of shares underlying the stock option vesting on the one-year anniversary of the employee&#8217;s employment commencement date and 1\/48th of the total number of shares vesting monthly &hellip; Continue reading &quot;Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-20\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-03T20:10:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/1890042\/Karyopharm_Therapeutics_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-20\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-20\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)\",\"datePublished\":\"2022-10-03T20:10:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-20\\\/\"},\"wordCount\":610,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-20\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1890042\\\/Karyopharm_Therapeutics_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-20\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-20\\\/\",\"name\":\"Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-20\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-20\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1890042\\\/Karyopharm_Therapeutics_Logo.jpg\",\"datePublished\":\"2022-10-03T20:10:41+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-20\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-20\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-20\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1890042\\\/Karyopharm_Therapeutics_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1890042\\\/Karyopharm_Therapeutics_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-20\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-20\/","og_locale":"en_US","og_type":"article","og_title":"Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","og_description":"PR Newswire NEWTON, Mass. , Oct. 3, 2022 \/PRNewswire\/ &#8212; Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that on September 30, 2022 (the Grant Date), the Company granted\u00a0a stock option to purchase 1,200 shares of Karyopharm&#8217;s common stock and an award of 800 restricted stock units (RSUs) to one newly-hired employee. The stock option has an exercise price of\u00a0$5.46 per share, the closing price of Karyopharm&#8217;s common stock on\u00a0the Grant Date. The stock option will vest over four years, with 25% of the total number of shares underlying the stock option vesting on the one-year anniversary of the employee&#8217;s employment commencement date and 1\/48th of the total number of shares vesting monthly &hellip; Continue reading \"Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-20\/","og_site_name":"Market Newsdesk","article_published_time":"2022-10-03T20:10:41+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/1890042\/Karyopharm_Therapeutics_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-20\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-20\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","datePublished":"2022-10-03T20:10:41+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-20\/"},"wordCount":610,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-20\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1890042\/Karyopharm_Therapeutics_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-20\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-20\/","name":"Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-20\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-20\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1890042\/Karyopharm_Therapeutics_Logo.jpg","datePublished":"2022-10-03T20:10:41+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-20\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-20\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-20\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/1890042\/Karyopharm_Therapeutics_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/1890042\/Karyopharm_Therapeutics_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-20\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/691441","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=691441"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/691441\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=691441"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=691441"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=691441"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}